Follow the people · Insider
Mike Mensinger
Mike Mensinger files insider transactions with the SEC as a chief product officer of Beta Bionics (BBNX). We hold 5 disclosed purchases and sales filed since 31 January 2025, 1 of them in the last 90 days.
- Files forBBNX
- Disclosed buys and sells5 in all, 1 in the last 90 days
- Last disclosure3 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 29 January 2025 — 2 September 2026Chief Product Officer · Beta Bionics (BBNX)33 Form 4 lines · source: SEC Form 4
Everything they disclosed
33 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 4,375 shares of Beta BionicsSEC Form 43 September 2026Common Stock · traded 2 September 2026 · filed 3 September 2026
- ▼ sold on the open market 4,378 shares of Beta BionicsSEC Form 43 June 2026Common Stock · traded 2 June 2026 · filed 3 June 2026
- was granted 91,520 shares of Beta Bionics (a derivative holding)SEC Form 413 March 2026Employee Stock Option (right to buy) · traded 27 February 2026 · filed 13 March 2026
- was granted 91,520 shares of Beta Bionics (a derivative holding)SEC Form 413 March 2026Employee Stock Option (right to buy) · traded 27 February 2026 · filed 13 March 2026
- was granted 109,105 shares of Beta BionicsSEC Form 43 March 2026Common Stock · traded 27 February 2026 · filed 3 March 2026
- ▼ sold on the open market 1,064 shares of Beta BionicsSEC Form 43 March 2026Common Stock · traded 2 March 2026 · filed 3 March 2026
- was granted 58,749 shares of Beta Bionics (a derivative holding)SEC Form 43 March 2026Employee Stock Option (right to buy) · traded 27 February 2026 · filed 3 March 2026
- was granted 58,749 shares of Beta Bionics (a derivative holding)SEC Form 43 March 2026Employee Stock Option (right to buy) · traded 27 February 2026 · filed 3 March 2026
- was granted 109,105 shares of Beta BionicsSEC Form 43 March 2026Common Stock · traded 27 February 2026 · filed 3 March 2026
- ▼ sold on the open market 1,064 shares of Beta BionicsSEC Form 43 March 2026Common Stock · traded 2 March 2026 · filed 3 March 2026
- ▼ sold on the open market 2,200 shares of Beta BionicsSEC Form 47 January 2026Common Stock · traded 6 January 2026 · filed 7 January 2026
- ▼ sold on the open market 2,200 shares of Beta BionicsSEC Form 47 January 2026Common Stock · traded 6 January 2026 · filed 7 January 2026
- ▼ sold on the open market 7,200 shares of Beta BionicsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 600 shares of Beta BionicsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 7,200 shares of Beta BionicsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 600 shares of Beta BionicsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 1,063 shares of Beta BionicsSEC Form 44 December 2025Common Stock · traded 2 December 2025 · filed 4 December 2025
- ▼ sold on the open market 1,089 shares of Beta BionicsSEC Form 44 September 2025Common Stock · traded 2 September 2025 · filed 4 September 2025
- ▼ sold on the open market 306 shares of Beta BionicsSEC Form 44 June 2025Common Stock · traded 2 June 2025 · filed 4 June 2025
- ▼ sold on the open market 708 shares of Beta BionicsSEC Form 44 June 2025Common Stock · traded 2 June 2025 · filed 4 June 2025
- ▼ sold on the open market 101 shares of Beta BionicsSEC Form 44 June 2025Common Stock · traded 2 June 2025 · filed 4 June 2025
- was granted 52,000 shares of Beta Bionics (a derivative holding)SEC Form 43 March 2025Employee Stock Option (right to buy) · traded 27 February 2025 · filed 3 March 2025
- was granted 35,000 shares of Beta BionicsSEC Form 43 March 2025Common Stock · traded 27 February 2025 · filed 3 March 2025
- converted 15,107 shares of Beta Bionics (a derivative holding)SEC Form 43 February 2025Series D Preferred Stock · traded 31 January 2025 · filed 3 February 2025
- converted 10,575 shares of Beta Bionics (a derivative holding)SEC Form 43 February 2025Class B Common Stock Warrant (right to buy) · traded 31 January 2025 · filed 3 February 2025
- exercised in-the-money options over 10,575 shares of Beta Bionics (a derivative holding)SEC Form 43 February 2025Class B Common Stock Warrant (right to buy) · traded 31 January 2025 · filed 3 February 2025
- was granted 236,553 shares of Beta Bionics (a derivative holding)SEC Form 43 February 2025Employee Stock Option (right to buy) · traded 31 January 2025 · filed 3 February 2025
- was granted 110,278 shares of Beta Bionics (a derivative holding)SEC Form 43 February 2025Employee Stock Option (right to buy) · traded 31 January 2025 · filed 3 February 2025
- converted 15,107 shares of Beta BionicsSEC Form 43 February 2025Common Stock · traded 31 January 2025 · filed 3 February 2025
- exercised in-the-money options over 10,575 shares of Beta BionicsSEC Form 43 February 2025Common Stock · traded 31 January 2025 · filed 3 February 2025
- ▼ sold on the open market 13 shares of Beta BionicsSEC Form 43 February 2025Common Stock · traded 31 January 2025 · filed 3 February 2025
- ▲ bought on the open market 33,350 shares of Beta BionicsSEC Form 43 February 2025Common Stock · traded 31 January 2025 · filed 3 February 2025
- was granted 110,278 shares of Beta Bionics (a derivative holding)SEC Form 431 January 2025Employee Stock Option (right to buy) · traded 29 January 2025 · filed 31 January 2025
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.